1231. Correlation of Obesity with Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from the CAPO International Cohort Study
Session: Poster Abstract Session: Clinical Infectious Diseases: Respiratory Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • Obesity poster.jpg (152.6 kB)
  • Background: Community-acquired pneumonia (CAP) is the leading cause of infectious death worldwide. Obesity is now recognized as a new worldwide pandemic. During the 2009 influenza A H1N1 pandemic, patients who were obese had poor clinical outcomes. Data are limited regarding the impact of obesity on the outcomes of patients with CAP not infected with 2009 Influenza A H1N1. The objective of this study was to compare mortality for hospitalized patients with CAP with normal body mass index (BMI) with patients with elevated BMI.

    Methods: This was a secondary data analysis of the Community-Acquired Pneumonia Organization (CAPO) international cohort study database. Log-binomial regression was used to determine the adjusted impact of obesity on mortality.

    Results: A total of 1,343 patients with normal BMI and 1,446 with increased BMI (obese) were included in the study. After adjusting for confounding factors, there was a 27% decreased risk of 30-day mortality for obese patients compared to those with a normal BMI.

    Conclusion: This study indicates that obesity is protective for mortality in hospitalized patients with CAP. Our data are in agreement with two recent publications indicating that obese patients with CAP have improved survival. Obese patients have an exaggerated inflammatory state at baseline that may be protective during an episode of CAP. A clear understanding of the protective effect of obesity on mortality may help to define new therapeutic strategies.

    Paula Peyrani, MD1, Robert Kelley, PhD1, Anupama Raghuram, MD1, Forest Arnold, DO, MSc, FIDSA1, Timothy Wiemken, PhD1, James Chalmers, MD2, Marcos I. Restrepo, MD, MSc3, Jose Bordon, MD, PhD4, Stefano Aliberti, MD5, Julio Ramirez, MD1 and the CAPO Investigators, (1)Division of Infectious Diseases, University of Louisville, Louisville, KY, (2)University of Dundee, Dundee, United Kingdom, (3)The Univ. of Texas Health Science Ctr. at San Antonio, San Antonio, TX, (4)Section of Infectious Diseases, Providence Hospital, Washington, DC, (5)University of Milan-Bicocca, Monza, Italy

    Disclosures:

    P. Peyrani, None

    R. Kelley, None

    A. Raghuram, None

    F. Arnold, None

    T. Wiemken, None

    J. Chalmers, None

    M. I. Restrepo, None

    J. Bordon, None

    S. Aliberti, None

    J. Ramirez, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.